12 / 16
Instituto Grifols, S.A.
Can Guasc, 2 08150 Parets del Vallès, Barcelona – SPAIN Tel. (34) 935 710 100
www.grifols.comIntroducing Flebogamma
®
DIF
IVIg to the Australian market
Concentration matters because every patient is different.
Committed to appropriate use of Flebogamma
®
DIF: available in 5% DIF or 10% DIF
1,2
Helping you choose the right concentration, at the lowest dosage, to meet each
patient’s individual needs
3
Committed to delivery of Flebogamma
®
DIF as a world leader in plasma collection
4
Our own vertically integrated supply of plasma helps ensure continuous production
of Flebogamma
®
DIF
Committed to service
To arrange a Flebogamma
®
DIF in-service please call 1800 091 961
or email
Australia_medinfo@grifols.comS
U
P
P
O
R
T
I
N
G
A
U
S
T
R
A
L
I
A
’
S
I
V
I
g
N
E
E
D
S
Quality
Reliability
Service
References: 1.
Flebogamma
®
5%DIF Product Information. January 2012.
2.
Flebogamma
®
10%DIF Product Information. 12 February 2013.
3.
National Blood Authority. Criteria for the clinical use of intravenous immunoglobulin in Australia.
2nd Edition, July 2012.
4.
Data on file.
Sponsored by: Grifols Australia Pty Ltd.
Unit 5/80 Fairbank Road, Clayton South VIC 3169, Australia. Tel: +61 3 9535 9333. Fax: +61 3 9535 9300. Email:
Australia_info@grifols.com.
Date of preparation: March 2016. GRI0004/HON
Human Normal
Immunoglobulin (IVIg)